- Home
- HG vs NVCR Comparison
HG vs NVCR Comparison
Compare HG & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | NVCR |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | Bermuda | Switzerland |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.2B |
| IPO Year | 2023 | 2015 |
Fundamental Metrics
Financial Performance| Metric | HG | NVCR |
|---|---|---|
| Price | $31.63 | $17.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $32.00 | $28.08 |
| AVG Volume (30 Days) | 422.8K | ★ 1.8M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | ★ 51.23 | 21.79 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $2,905,524,000.00 | $655,353,000.00 |
| Revenue This Year | $1.80 | $7.72 |
| Revenue Next Year | $12.52 | $6.74 |
| P/E Ratio | $24.33 | ★ N/A |
| Revenue Growth | ★ 24.70 | 8.28 |
| 52 Week Low | $20.47 | $9.82 |
| 52 Week High | $33.72 | $20.05 |
Technical Indicators
Market Signals| Indicator | HG | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 66.10 |
| Support Level | $29.70 | $12.48 |
| Resistance Level | $31.88 | $18.92 |
| Average True Range (ATR) | 0.87 | 0.90 |
| MACD | 0.05 | -0.08 |
| Stochastic Oscillator | 63.83 | 70.74 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.